Treatment of Corneal Infiltrates Secondary to Epidemic Keratoconjunctivitis

PHASE4CompletedINTERVENTIONAL
Enrollment

51

Participants

Timeline

Start Date

April 1, 2017

Primary Completion Date

April 1, 2019

Study Completion Date

April 1, 2019

Conditions
Adenoviral Keratoconjunctivitis
Interventions
DRUG

FLUCON®

"The drug was prescribed monthly according to the predefined regimen. It was not namely specefied in the prescription and was delivered by the hospital pharmacy according to the randomisation list.The subjects were masked to the contents and were instructed to return the empty tubes on monthly visit, wherein 1 pack of topical treatment was provided to them. Neither the patient nor the ophthalmologist knew the allocated treatment. No other medication was allowed during the trial. Duration of the whole regimen was six months. The study included an extra month after the end of the regimen. It was called wash-out . Patients who had less than one month of treatment or an uncontrolled treatment side effect or who presented a degenerative iron line were excluded from the rest of the regimen."

DRUG

Cyclosporine A eye drops 0.5%

The same regimen was prescribed for both treatments in order to preserve the double-blind characteristic. Cyclosporine eye drops 0.5%, was prepared from an oral solution of cyclosporine (Sandimmun®) and combined with castor oil, both sterilized by filtration. The preparation was carried out in a pharmacotechnical laboratory where a controlled atmosphere area was dedicated to ophthalmic preparations. The castor oil-Sandimmun® solution mixture is made in a sterile receptacle. After stirring, the mixture is distributed into sterile low density polyethylene bottles. A sterile insert and cap including a tamper-evident seal were placed on each bottle. A content control was then carried out on each batch produced. A sterility test was done on a batch of each day of preparation. Each bottle of each batch is then cleaned, polished, labeled and then packaged in a pre-printed box with an adapted notice. The stability was fixed at 6 months before opening and at 15 days after opening.

Trial Locations (1)

Unknown

Military Hospital of Tunis, Tunis

All Listed Sponsors
lead

Military Hospital of Tunis

OTHER

NCT04376970 - Treatment of Corneal Infiltrates Secondary to Epidemic Keratoconjunctivitis | Biotech Hunter | Biotech Hunter